Inspections, Compliance, Enforcement, and Criminal Investigations
Encompass Group, LLC - Close Out Letter 9/18/12
| Public Health Service Food and Drug Administration |
New Orleans District |
September 18, 2012
Michael Spurlock, CEO
Encompass Group, LLC
615 Macon Road
McDonough, Georgia 30253
Dear Mr. Spurlock:
The Food and Drug Administration (FDA) completed an evaluation of your firm's corrective actions in response to our Warning Letter No. 2012-NOL-07 dated December 27, 2011. Based on our evaluation, it appears you have addressed the violations contained in this Warning Letter. Future FDA inspections and regulatory activities will further assess the adequacy and sustainability of these corrections.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to assure sustained compliance with the Federal Food, Drug, and Cosmetic Act and its implementing regulations or with other relevant legal authority. The FDA expects you and your firm to maintain compliance and will continue to monitor your state of compliance. This letter does not preclude any future regulatory action should violations be observed during a subsequent inspection or through other means.
Sincerely,
/S/
Kari L. Batey
Acting Compliance Branch Director
New Orleans District
cc: Patrick F. Frank
Quality Value Relationship Manager
Albahealth, LLC
425 North Gateway Boulevard
Rockwood, Tennessee 3 7854





Department of Health and Human Services

